<DOC>
	<DOCNO>NCT00003353</DOCNO>
	<brief_summary>RATIONALE : High-dose chemotherapy may destroy amyloid-producing cell bone marrow . Peripheral stem cell transplantation PURPOSE : Phase II trial study effectiveness high dose melphalan plus peripheral stem cell transplantation treat patient primary systemic amyloidosis .</brief_summary>
	<brief_title>High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Treating Patients With Primary Systemic Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : I. Assess response rate overall survival patient biopsy proven primary amyloidosis follow treatment myeloablative chemotherapy hematopoietic stem cell reconstitution . II . Evaluate toxicity high dose melphalan patient population . OUTLINE : Patients receive filgrastim ( G-CSF ) subcutaneously daily begin day 1 peripheral blood stem cell ( PBSC ) collection period continue PBSC collection complete . PBSC collect begin day 5 collection period continue final target cell count reach maximum 7 collection . If sufficient PBSCs harvest within maximum 7 collection , patient remove study . Within 30 day PBSC collection , patient receive melphalan IV day -1 infusion period PBSC infusion day 0 . The infusion period continue day 30 . Patients receive G-CSF subcutaneously daily start day 1 continue blood count recover . Patients follow every 3 month 2 year , every 3 month 3 additional year , yearly thereafter . PROJECTED ACCRUAL : A maximum 33 patient accrue study 2 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary amyloidosis Must presence paraprotein serum urine determine immunoelectrophoresis/immunofixation No primary amyloidosis manifest carpal tunnel syndrome purpura No history secondary , familial , localized amyloidosis No evidence overt multiple myeloma : Lytic bone disease pathological fracture OR At least 30 % plasma cell bone marrow PATIENT CHARACTERISTICS : Age : 18 70 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL Alkaline phosphatase great 1000 u/L le 4 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : Confirmed echocardiogram : Ejection fraction least 50 % Interventricular septal thickness great 15 mm No New York Heart Association classification IIIV Pulmonary : DLCO least 50 % FVC least 60 % FEV1 least 55 % Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection No malignancy within past 5 year except surgically treat carcinoma situ cervix , nonmelanoma skin cancer , indolent prostate cancer No known sensitivity E. coli derivative PRIOR CONCURRENT THERAPY : Biologic therapy : Prior interferon allow Chemotherapy : At least 4 week since prior melphalan Lifetime cumulative dose melphalan great 150 mg No great 2 prior course chemotherapy Endocrine therapy : Prior dexamethasone allow Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>